Xenon Pharmaceuticals Inc. Share Price
XENEXenon Pharmaceuticals Inc. Stock Performance
Open $41.49 | Prev. Close $41.37 | Circuit Range N/A |
Day Range $40.80 - $41.61 | Year Range $26.74 - $46.50 | Volume 52,050 |
Average Traded $41.37 |
Xenon Pharmaceuticals Inc. Share Price Chart
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $41.49 | $41.42 | +2.47% |
05-Feb-26 | $41.45 | $40.42 | -1.91% |
04-Feb-26 | $42.21 | $41.20 | -2.13% |
03-Feb-26 | $42.27 | $42.10 | +1.59% |
02-Feb-26 | $41.22 | $41.44 | +0.95% |
30-Jan-26 | $41.73 | $41.05 | -1.75% |
29-Jan-26 | $41.83 | $41.78 | -0.43% |